Navigation Links
Cephalon Announces Definitive Agreement to Acquire Gemin X
Date:3/21/2011

proval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Contacts

Cephalon

Media:
Natalie de Vane
Senior Director, Corporate Communications & Public Affairs
O: 610.727.6536
C. 610.999.8756
ndevane@cephalon.com

Fritz Bittenbender
VP, Public Affairs
O: 610.883.5855
C: 610.457.7041
fbittenb@cephalon.com

Investors:  
Chip Merritt
VP, Investor Relations
610.738.6376
cmerritt@cephalon.com

Joseph Marczely
Manager, Investor Relations
610.883.5894
jmarczely@cephalon.com

Gemin X'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... announce that TUV-SUD and The Medicinal Evaluation Board ... has granted its request for a label expansion ... initially approved in July 2013 for use in ...
(Date:9/22/2014)... PLEASANTON, Calif. , Sept. 22, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... D. Keith Grossman has been appointed President and ... F. Burbach , who has stepped down from his ... advisor to the company through the first quarter of ...
(Date:9/22/2014)... Sept. 22, 2014 Auxilium Pharmaceuticals, Inc. ... company, today announced that its Board of Directors ... conditional proposal from Endo International plc ("Endo") and, ... advisors, has unanimously determined it is not a ... merger agreement with QLT Inc. ("QLT") and has ...
Breaking Medicine Technology:Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
... Based on its recent analysis of the ... Hybridyne Technologies, Inc. with the 2010 North American ... the Year. (Logo:   http://photos.prnewswire.com/prnh/20081117/FSLOGO ... ProxiScan™, recently approved by the FDA, is ...
... Upstate New York Laboratory Robotics Interest Group (LRIG) ... Society of Mechanical Engineers (ASME) will be hosting ... 27, 2010 entitled "Unconventional High-Throughput Applications," featuring Pankaj ... Seth Cohen, Ph.D., Senior Director Microfluidics Applications, Caliper ...
Cached Medicine Technology:Frost & Sullivan Award Highlights Hybridyne Technologies' Outstanding Technology Innovation 2Frost & Sullivan Award Highlights Hybridyne Technologies' Outstanding Technology Innovation 3Frost & Sullivan Award Highlights Hybridyne Technologies' Outstanding Technology Innovation 4Upstate New York Laboratory Robotics Interest Group (LRIG) to Host Free Symposium and Exhibition 2
(Date:9/22/2014)... Malaysia today became a founding partner in the Global ... to promoting young talent in science, technology, engineering and ... New York Academy of Sciences (NYAS), Malaysian Prime Minister ... Monday Sept. 22. , With the goal of developing ... countries by 2020, the initiative will create a host ...
(Date:9/22/2014)... September 22, 2014 This Flash Report ... stakeholder management needs for the Prostate Cancer market. , ... on stakeholder strategies for any launching Prostate Cancer product:, ... differentiation within an increasingly crowded market , ... impact of identifying community-based thought leaders and stakeholders ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 The R&D ... the recent years. The statistically important data received from ... of cancer vaccines. The primary challenge to the development ... about the exact mechanism of how a human’s immune ... various results in different individuals owing to known factors ...
(Date:9/22/2014)... Sept. 22, 2014 (HealthDay News) -- Two new prescription ... (FDA) may provide some relief for people with migraine ... a new study. One device -- the Cefaly ... device -- the Cerena -- is meant to be ... news release. "Patients have been looking for alternative ...
(Date:9/22/2014)... Nanuet, NY (PRWEB) September 22, 2014 ... Blindness, Rockland Chrysler Jeep Dodge Ram is launching an ... Blind Egg Challenge (#blindeggchallenge or #ffbBEC) aims to raise ... Egg Challenge involves throwing an egg in the air ... at least three others and if a nominee does ...
Breaking Medicine News(10 mins):Health News:Growing scientists: World's future jobs are rooted in STEM 2Health News:Growing scientists: World's future jobs are rooted in STEM 3Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2
... ... in pursing careers in medical transcription and medical coding and billing. , ... Provo, Utah (PRWEB) June 5, ... Community College in Roxboro, N.C. to offer training to individuals interested in pursing careers ...
... announced today its decision to expand its use of ... sanitizer, to all its service centers nationwide after testing ... the first major healthcare laundry processor to implement the ... wash process will elevate the standard of cleanliness in ...
... Univision, People en Espanol, Ser Padres and impreMedia health expert Aliza ... Doctora Aliza (TM), announced the launch of her Spanish-language health hub ... http://www.newscom.com/cgi-bin/prnh/20090604/SF28145 ) , , " VidaySalud.com ... wellness tools in Spanish on the web. It includes ...
... Gift Cards, Inspiring Star Cards Make Giving Easy , ... Maggiano,s Little Italy(R) restaurants begin the sixth annual "Eat-A-Dish ... five Chicago-area Maggiano,s are taking part in the program ... the nonprofit organization that makes wishes come true for ...
... Up 191% - , , - Total Net Sales in Line ... be Held Today at 3:30 pm Central Time - ... UPI ), a medical device company that develops, manufactures and markets innovative ... fourth quarter and full year ended March 31, 2009. Net sales ...
... could mutate and become more dangerous as it travels from ... In what would seem to be some encouraging news in ... official said Thursday that samples of the virus from points ... in the United States. , "We have tested isolates from ...
Cached Medicine News:Health News:Career Step Partners with Piedmont Community College to Help Students Gain Careers in Growing Healthcare Industry 2Health News:Angelica Corporation Raises Bar Again for Increased Patient Safety 2Health News:Univision's Doctora Aliza Launches VidaySalud.com(TM) 2Health News:Maggiano's Little Italy(R) Celebrates Sixth Annual 'Eat-A-Dish for Make-A-Wish(R)' in Chicago 2Health News:Maggiano's Little Italy(R) Celebrates Sixth Annual 'Eat-A-Dish for Make-A-Wish(R)' in Chicago 3Health News:Maggiano's Little Italy(R) Celebrates Sixth Annual 'Eat-A-Dish for Make-A-Wish(R)' in Chicago 4Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 2Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 3Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 4Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 5Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 6Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 7Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 8Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 9Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 10Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 11Health News:Global Testing Shows No Variation in Swine Flu Virus 2Health News:Global Testing Shows No Variation in Swine Flu Virus 3Health News:Global Testing Shows No Variation in Swine Flu Virus 4Health News:Global Testing Shows No Variation in Swine Flu Virus 5Health News:Global Testing Shows No Variation in Swine Flu Virus 6Health News:Global Testing Shows No Variation in Swine Flu Virus 7Health News:Global Testing Shows No Variation in Swine Flu Virus 8Health News:Global Testing Shows No Variation in Swine Flu Virus 9Health News:Global Testing Shows No Variation in Swine Flu Virus 10Health News:Global Testing Shows No Variation in Swine Flu Virus 11
Designed to meet the requirements of reagent grade water for routine analysis....
... L/min of Type I ultrapure water, , ... Plus System is designed to provide the ... pretreated by reverse osmosis, distillation or deionization. ... quality which exceeds Type I ASTM/CAP/NCCLS specifications.,The ...
... Basic Laboratory Needs, Synergy systems produce ultrapure water ... 1 to 1.2 L/min to meet the basic ... incorporates a dual-wavelength UV lamp (185 nm and ... of organic contaminants (< 5 ppb TOC when ...
... Compact System Produces Type I Water Directly from ... designed for scientists who need 5 to 15 ... not have easy access to acceptable quality pretreated ... 0.6 L/min of ultrapure (Type I) water on ...
Medicine Products: